Korea’s Ilyang Wins KFDA Approval For 2nd-Line Leukemia Drug Supect; Could Compete With Gleevec
This article was originally published in PharmAsia News
Executive Summary
Ilyang gears up to launch its chronic myeloid leukemia drug in Korea and other Asian markets for second-line treatment. The drug could eventually compete with Novartis AG's Gleevec (imatinib), which is approved for first-line treatment.